Cullinan Therapeutics, Inc.
CGEM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | -358.4% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | -346.1% |
| EPS Diluted | -3.11 | -3.69 | 2.38 | -1.48 |
| % Growth | 15.7% | -255% | 260.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |